20200709 PR Hypertrust Transgene EN
Category: TG4050
Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation
Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
20200515_AACR myvac curtain raiser EN
Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
20200107 PR TG4050 FPI – EN
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
20190916 PR ANSM TG4050 EN
Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
20190710 PR MHRA TG4050 EN
Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
20190513 PR IND TG4050 EN
Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
20190305-PR-NEC-Agreement-US-1
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur Human Vaccines and Immunotherapeutics, August 2017 – Read the article Publication
